TW202140534A - 個人化醫藥 - Google Patents

個人化醫藥 Download PDF

Info

Publication number
TW202140534A
TW202140534A TW110102357A TW110102357A TW202140534A TW 202140534 A TW202140534 A TW 202140534A TW 110102357 A TW110102357 A TW 110102357A TW 110102357 A TW110102357 A TW 110102357A TW 202140534 A TW202140534 A TW 202140534A
Authority
TW
Taiwan
Prior art keywords
seq
tcr
hla
tcrs
cdr3a
Prior art date
Application number
TW110102357A
Other languages
English (en)
Chinese (zh)
Inventor
安東尼奧 貝圖勒提
子忠 何
曉芳 許
容璟 陳
璐恩 韋
Original Assignee
新加坡商來恩生物醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 新加坡商來恩生物醫藥有限公司 filed Critical 新加坡商來恩生物醫藥有限公司
Publication of TW202140534A publication Critical patent/TW202140534A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
TW110102357A 2020-01-21 2021-01-21 個人化醫藥 TW202140534A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2020/051439 WO2021148110A1 (en) 2020-01-21 2020-01-21 Hbv specific tcr library and its use as personalised medicine
WOPCT/EP2020/051439 2020-01-21

Publications (1)

Publication Number Publication Date
TW202140534A true TW202140534A (zh) 2021-11-01

Family

ID=69187789

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110102357A TW202140534A (zh) 2020-01-21 2021-01-21 個人化醫藥

Country Status (7)

Country Link
US (1) US20230061817A1 (cg-RX-API-DMAC7.html)
EP (1) EP4093759A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023512631A (cg-RX-API-DMAC7.html)
KR (1) KR20220148809A (cg-RX-API-DMAC7.html)
CN (1) CN115335397A (cg-RX-API-DMAC7.html)
TW (1) TW202140534A (cg-RX-API-DMAC7.html)
WO (2) WO2021148110A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156889B (zh) * 2018-02-14 2023-03-10 中国科学院广州生物医药与健康研究院 高亲和力HBs T细胞受体
US20250273289A1 (en) * 2024-02-23 2025-08-28 Tata Consultancy Services Limited Insilico method and system for designing a baseline peptide bioreceptor for sensing a biomarker for dysglycemic disorders
CN121319150B (zh) * 2025-12-16 2026-04-14 温州医科大学 一种同时识别hbv核心抗原表位及包膜蛋白表位的tcr及其编码序列

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2288700B1 (en) * 2008-05-09 2017-02-08 Agency for Science, Technology And Research Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
JP6895975B2 (ja) * 2016-01-06 2021-06-30 ヘルス リサーチ インコーポレイテッドHealth Research, Inc. 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
US11576932B2 (en) * 2016-03-31 2023-02-14 Lion Tcr Pte. Ltd. Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR)
SG11201901634UA (en) * 2016-09-23 2019-04-29 Lion Tcr Pte Ltd An hbv antigen specific binding molecules and fragments thereof
CN107827959B (zh) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途

Also Published As

Publication number Publication date
CN115335397A (zh) 2022-11-11
EP4093759A1 (en) 2022-11-30
WO2021148547A1 (en) 2021-07-29
US20230061817A1 (en) 2023-03-02
JP2023512631A (ja) 2023-03-28
WO2021148110A1 (en) 2021-07-29
KR20220148809A (ko) 2022-11-07

Similar Documents

Publication Publication Date Title
JP7340638B2 (ja) Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用
US20230248770A1 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
JP6588514B2 (ja) 癌を治療するためのキメラ抗原受容体改変t細胞の使用
CN108778291B (zh) 包含重组t细胞受体的组合物和文库以及使用重组t细胞受体的方法
CN111566201A (zh) 使用用于表达嵌合抗原受体(car)或转基因t细胞受体(tcr)的病毒载体转导细胞的方法
JP2022087340A (ja) 幹細胞様メモリーt細胞の生成および養子免疫療法における使用
JP2019501956A (ja) 免疫療法に使用するための組成物
TW202206453A (zh) 表現嵌合抗原受體之病毒特異性免疫細胞
WO2020112815A1 (en) Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
US20240376429A1 (en) Virus-specific immune cells expressing chimeric antigen receptors
JP2023512631A (ja) Hbv特異的tcrライブラリーおよび個別化医療としてのその使用
CN117106061B (zh) 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用
US20260021140A1 (en) HBV Surface Antigen Specific T Cell Receptors And Uses Thereof
Liu et al. Cancer immunotherapy using T-cell receptor engineered T cell
Ramírez et al. Impact of T cell selection methods in the success of clinical adoptive immunotherapy
JP7774284B2 (ja) Mrp3標的遺伝子改変t細胞
WO2024243807A1 (zh) 靶向ny-eso-1的高亲和力t细胞受体及其应用
Koh Immune response during hepatitis B virus infection and reconstitution of HBV-specific immunity using T cells redirected against HBV